ONCODESIGN: Feedback Investor Day: ODS-101 a promising opportunity but still a long way to go | CORPORATE | EUR15(+39%)
ONCODESIGN - CORPORATE | EUR15(+39%)Feedback Investor Day: ODS-101 a promising opportunity but still a long way to go
RIPK2: an untapped opportunity in inflammatory diseases
ODS-101: Oncodesign’s flagship should reach clinic in 2022
CPI-induced colitis: a proof-of-concept indication
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.